LP-108 is under clinical development by Newave Pharmaceutical and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase I drugs for Myelodysplastic Syndrome have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LP-108’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LP-108 overview
LP-108 is under development for the treatment of relapsed and refractory chronic lymphocytic leukemia, myelodysplastic syndromes, chronic myelomonocytic leukemia, acute myeloid leukemia (AML), Waldenstrom macroglobulinemia, mantle cell lymphoma, follicular lymphoma, marginal zone B-cell lymphoma and diffuse large B-cell lymphoma. It is administered by oral route. It acts by targeting B cell lymphoma 2 (Bcl 2).
For a complete picture of LP-108’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.